Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

The Case ∣ Hyperbicarbonatemia in a patient with Waldenstrom's macroglobulinemia. Pseudohyperbicarbonatemia due to paraproteinemia.

Krish P, Jhaveri KD.

Kidney Int. 2012 Mar;81(6):603-5. doi: 10.1038/ki.2011.427. No abstract available.

2.

Successful treatment with Rituximab and Bendamustine in a patient with newly diagnosed Waldenström's Macroglobulinemia complicated by Bing-Neel syndrome.

Varettoni M, Marchioni E, Bonfichi M, Picchiecchio A, Arcaini L, Arbasino C, Gotti M, Da Vià M, Delmonte M, Sciarra R, Cazzola M.

Am J Hematol. 2015 Aug;90(8):E152-3. doi: 10.1002/ajh.24059. Epub 2015 May 29. No abstract available.

3.

Myelopathy from Waldenström's macroglobulinemia: improvement after Rituximab therapy.

Liberato B, Riethmuller A, Comenzo RL, Lis E, Raizer JJ.

J Neurooncol. 2003 Jun;63(2):207-11.

PMID:
12825826
4.

Waldenstrom's macroglobulinemia presenting as a perinephric mass.

Therasse CJ, Casalino DD.

J Urol. 2011 Nov;186(5):2067-8. doi: 10.1016/j.juro.2011.08.013. Epub 2011 Sep 25. No abstract available.

PMID:
21944982
5.

Bendamustine therapy in patients with relapsed or refractory Waldenström's macroglobulinemia.

Treon SP, Hanzis C, Tripsas C, Ioakimidis L, Patterson CJ, Manning RJ, Sheehy P.

Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):133-5. doi: 10.3816/CLML.2011.n.030.

PMID:
21454214
6.

Hepatocellular carcinoma followed by Waldenström's macroglobulinemia: a case report.

Hasegawa K, Kubota K, Hirai H, Imai Y, Midorikawa Y, Makuuchi M.

Hepatogastroenterology. 2000 May-Jun;47(33):842-5. Review.

PMID:
10919044
7.

Improvement of the thermal amplitude after rituximab treatment for cold agglutinin disease with Waldenström's macroglobulinemia.

Hattori N, Ishii N, Ariizumi H, Adachi D, Matsuda I, Nakamaki T, Tomoyasu S.

Ann Hematol. 2010 Jan;89(1):103-4. doi: 10.1007/s00277-009-0773-z. Epub 2009 Jun 10. No abstract available.

PMID:
19513714
8.

Fludarabine therapy in a patient with progressive symptomatic Waldenström's macroglobulinemia.

Hałaburda K, Hellmann A.

Acta Haematol Pol. 1994;25(1):63-7.

PMID:
8209618
9.

Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemia.

Ciccarelli BT, Yang G, Hatjiharissi E, Ioakimidis L, Patterson CJ, Manning RJ, Xu L, Liu X, Tseng H, Gong P, Sun J, Zhou Y, Treon SP.

Clin Lymphoma Myeloma. 2009 Mar;9(1):56-8. doi: 10.3816/CLM.2009.n.014.

PMID:
19362974
10.

Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia.

Treon SP, Branagan AR, Hunter Z, Santos D, Tournhilac O, Anderson KC.

Ann Oncol. 2004 Oct;15(10):1481-3.

PMID:
15367407
11.

Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma.

Hensel M, Villalobos M, Kornacker M, Krasniqi F, Ho AD.

Clin Lymphoma Myeloma. 2005 Sep;6(2):131-5.

PMID:
16231851
12.

The tyranny of the anecdote: Waldenstrom's macroglobulinemia and scleritis.

Rosenbaum JT, Becker MD.

Ocul Immunol Inflamm. 2000 Jun;8(2):111-3.

PMID:
10980683
13.

Resolution of Waldenström's macroglubulinemia related isolated neutropenia by immunochemotherapy.

van Gelder M, van Marion A, Goossens V, Bommer M, Leblond V.

Am J Hematol. 2011 Apr;86(4):380-2. doi: 10.1002/ajh.21990. No abstract available.

14.

Appropriateness of applying the response criteria for multiple myeloma to Waldenstrom's macroglobulinemia?

Bladé J, Montoto S, Rosiñol L, Montserrat E.

Semin Oncol. 2003 Apr;30(2):329-31.

PMID:
12720163
15.

Waldenstrom's macroglobulinaemia: to treat or not to treat?

Sundriyal D, Kumar N, Kotwal S, Shirsi N.

BMJ Case Rep. 2014 Nov 20;2014. pii: bcr2014206875. doi: 10.1136/bcr-2014-206875.

16.

Severe immune thrombocytopenia secondary to Waldenström's macroglobulinemia with anti-GPIb/IX monoclonal IgM antibody.

Yamanouchi J, Hato T, Niiya T, Azuma T, Yasukawa M.

Ann Hematol. 2014 Apr;93(4):711-2. doi: 10.1007/s00277-013-1857-3. Epub 2013 Jul 28. No abstract available.

PMID:
23892928
17.

Waldenström's macroglobulinaemia: laboratory diagnosis and treatment.

Owen RG, Johnson SA, Morgan GJ.

Hematol Oncol. 2000 Jun;18(2):41-9. Review. No abstract available.

PMID:
10960874
18.

Waldenström macroglobulinaemia and intestinal lymphangiectasia.

Cooke RE, Kalnins RM, Ho WK.

Br J Haematol. 2014 Nov;167(3):292. doi: 10.1111/bjh.13041. Epub 2014 Jul 21. No abstract available.

PMID:
25039993
19.

Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemia.

Ioakimidis L, Patterson CJ, Hunter ZR, Soumerai JD, Manning RJ, Turnbull B, Sheehy P, Treon SP.

Clin Lymphoma Myeloma. 2009 Mar;9(1):62-6. doi: 10.3816/CLM.2009.n.016.

PMID:
19362976
20.

Prognosis and treatment of Waldenström's macroglobulinemia.

Louw VJ, Webb MJ.

Transfus Apher Sci. 2010 Apr;42(2):193-7. doi: 10.1016/j.transci.2010.01.017. Epub 2010 Feb 8. Review.

PMID:
20117052

Supplemental Content

Support Center